A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center

International Journal of Hematology

Volumn 91, Issue 5, 2010, Pages 826-830

  Chiang, Joen ^a   Chan, Alexandre ^a,b   Shih, Vivianne ^a   Hee, Siew Wan ^a   Tao, Miriam ^a   Lim, Soon Thye ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Rapid infusion; Resource utilization; Rituximab

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; METOCLOPRAMIDE; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABNORMAL SENSATION; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANGIONEUROTIC EDEMA; ARTICLE; ASIA; BRONCHOSPASM; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CARDIOGENIC SHOCK; CHEST TIGHTNESS; CHILL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FEVER; HEALTH CARE UTILIZATION; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOTENSION; HYPOXIA; LUNG INFILTRATE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATIENT SAFETY; RAPID INFUSION; URTICARIA; VOMITING; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PROSPECTIVE STUDY; TIME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ASIA; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 77954539017     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0583-z     Document Type: Article

References (9)

1. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Non-Hodgkin's Lymphomas. Version 1.2010.
2. Rituximab (Rituxan). South San Francisco: Genetech Inc. 2008.
3. A Salar D Casao M Cervera C Pedro M Calafell E Abella, et al. 2006 Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution Eur J Haematol 77 4 338 340 10.1111/j.1600-0609.2006.00713.x 1:CAS:528:DC%2BD28XhtF2lsLnJ 16856919 (Pubitemid 44337328)
4. LH Sehn J Donaldson A Filewich C Fitzgerald KK Gill N Runzer, et al. 2007 Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting Blood 109 10 4171 4173 10.1182/blood-2006-11- 059469 1:CAS:528:DC%2BD2sXls1anu7o%3D 17244675 (Pubitemid 46743380)
5. Gibbs S, Pout G, Wimperis J. Rapid infusion rituximab is as effective and safe as conventional infusion regimes in the treatment of diffuse large B cell lymphoma: a 2 year prospective study. Haematologica. 2007;92(Suppl. 2):264.
6. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004;103:4416-23.
7. M Tuthill T Crook T Corbet J King A Webb 2009 Rapid infusion of rituximab over 60 min Eur J Haematol 82 4 322 325 10.1111/j.1600-0609.2009.01215.x 1:CAS:528:DC%2BD1MXksF2ht78%3D 19220420
8. M Provencio S Cerdeira F Bonilla A Sanchez P Espana 2006 Rapid infusion rituximab in lymphoma treatment Ann Oncol 17 6 1027 1028 10.1093/annonc/mdj103 1:STN:280:DC%2BD283nslegsA%3D%3D 16322113 (Pubitemid 43779000)
9. M Siano E Lerch L Negretti E Zucca D Rodriguez-Abreu, et al. 2008 A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function Clin Cancer Res 14 23 7935 7939 10.1158/1078-0432.CCR-08-1124 1:CAS:528: DC%2BD1cXhsVegt7%2FP 19047125